Literature DB >> 30553471

Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors.

Wei Xie1, Sa A Wang1, Shimin Hu1, Jie Xu1, L Jeffrey Medeiros1, Guilin Tang2.   

Abstract

Myeloproliferative neoplasms (MPN) associated with ABL1-ETV6 fusions are rare and poorly characterized. To date, less than 20 cases of ABL1-ETV6+ MPN have been reported. We report a 47-year-old man who presented with MPN with clinicopathologic features resembling chronic myeloid leukemia, but there was no evidence of t(9;22)(p34.1;q11.2) or BCR-ABL1 fusion. Conventional cytogenetics and fluorescence in situ hybridization analysis showed ins(12;9)(p13;q34q34) that led to ETV6-ABL1 fusion. The patient responded well to tyrosine kinase inhibitor therapy and achieved remission for 7 years.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ABL1-ETV6 rearrangement; Myeloproliferative neoplasm; Tyrosine kinase inhibitors

Mesh:

Substances:

Year:  2018        PMID: 30553471     DOI: 10.1016/j.cancergen.2018.08.002

Source DB:  PubMed          Journal:  Cancer Genet


  2 in total

Review 1.  Updates on eosinophilic disorders.

Authors:  Alexandar Tzankov; Kaaren K Reichard; Robert P Hasserjian; Daniel A Arber; Attilio Orazi; Sa A Wang
Journal:  Virchows Arch       Date:  2022-09-07       Impact factor: 4.535

2.  Myeloid/lymphoid neoplasms with eosinophilia/ basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition.

Authors:  JinJuan Yao; Lianrong Xu; Umut Aypar; Howard J Meyerson; Dory Londono; Qi Gao; Jeeyeon Baik; James Dietz; Ryma Benayed; Allison Sigler; Mariko Yabe; Ahmet Dogan; Maria E Arcila; Mikhail Roshal; Yanming Zhang; Michael J Mauro; Wenbin Xiao
Journal:  Haematologica       Date:  2021-02-01       Impact factor: 9.941

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.